# Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT05348577** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1035 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** capivasertib
- **DRUG:** docetaxel
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT05348577
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-25
- **Primary completion:** 2026-03-04
- **Final completion:** 2026-03-04
- **Target enrollment:** 1035 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348577, "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05348577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*